跳至主要内容
临床试验/NCT01054703
NCT01054703终止不适用

Clinical Evaluation of the Safety and Feasibility of the Ethmoid Sinus Spacer and Access System With Drug (SPACER)

Integra LifeSciences Corporation2 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2007年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
14
试验地点
2
主要终点
Occurrence of Adverse Events at the Time of the Procedure and Cumulatively up to 6 Weeks Post-implant

研究概览

简要总结

Evaluation of treatment of the ethmoid sinuses with the Ethmoid Sinus Spacer and Access system

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age > 21 years old
  • Both male and female
  • Ethmoid disease on CT scan
  • At least one non-ethmoid sinus requiring treatment
  • Failed medical management and symptomatic

排除标准

  • Previous ethmoid surgery
  • Not sufficient room for placement of Spacer
  • Patient requires septoplasty
  • Has received steroid treatment with in 2 weeks
  • Extensive sinonasal osteoneogenesis preventing device placement
  • Sinonasal tumors or obstructive lesions
  • History of facial trauma that distorts sinus anatomy
  • Asthmatic patients with aspirin sensitivity
  • Pregnant or lactating females

结局指标

主要结局

Occurrence of Adverse Events at the Time of the Procedure and Cumulatively up to 6 Weeks Post-implant

时间窗: Procedural and 6 weeks post-implant

次要结局

  • Efficacy: Improvement in Ethmoid Sinus Health as Demonstrated by CT Scan and Quality-of-life Measures(1 wk, 2wk, 4wk, 6wk)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Clinical Evaluation of the Ethmoid Sinus Spacer | 临床试验